UBS upgraded GE HealthCare Technologies from Sell to Neutral on May 21, 2026. Fintel notes an analyst price forecast implying 29.54% upside, which is a constructive signal for the stock despite the still-neutral stance. The update is primarily analyst-driven and likely to have limited but positive stock-specific impact.
UBS upgraded GE HealthCare Technologies from Sell to Neutral on May 21, 2026. Fintel notes an analyst price forecast implying 29.54% upside, which is a constructive signal for the stock despite the still-neutral stance. The update is primarily analyst-driven and likely to have limited but positive stock-specific impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
